vs

Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and SUBURBAN PROPANE PARTNERS LP (SPH). Click either name above to swap in a different company.

SUBURBAN PROPANE PARTNERS LP is the larger business by last-quarter revenue ($370.4M vs $196.9M, roughly 1.9× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -0.8%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-67.5M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -13.8%).

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.

Suburban Propane Partners LP is a leading U.S. distributor of propane, natural gas, heating oil and related energy products, serving residential, commercial, industrial and agricultural customers across the country. It also provides HVAC system installation, maintenance and repair services, catering mainly to suburban and off-grid communities.

PCRX vs SPH — Head-to-Head

Bigger by revenue
SPH
SPH
1.9× larger
SPH
$370.4M
$196.9M
PCRX
Growing faster (revenue YoY)
PCRX
PCRX
+5.9% gap
PCRX
5.1%
-0.8%
SPH
More free cash flow
PCRX
PCRX
$110.9M more FCF
PCRX
$43.5M
$-67.5M
SPH
Faster 2-yr revenue CAGR
PCRX
PCRX
Annualised
PCRX
8.5%
-13.8%
SPH

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
PCRX
PCRX
SPH
SPH
Revenue
$196.9M
$370.4M
Net Profit
$45.8M
Gross Margin
79.5%
64.7%
Operating Margin
1.2%
18.3%
Net Margin
12.4%
Revenue YoY
5.1%
-0.8%
Net Profit YoY
135.7%
EPS (diluted)
$0.05
$0.69

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PCRX
PCRX
SPH
SPH
Q4 25
$196.9M
$370.4M
Q3 25
$179.5M
$211.4M
Q2 25
$181.1M
$260.1M
Q1 25
$168.9M
$587.7M
Q4 24
$187.3M
$373.3M
Q3 24
$168.6M
$208.6M
Q2 24
$178.0M
$254.6M
Q1 24
$167.1M
$498.1M
Net Profit
PCRX
PCRX
SPH
SPH
Q4 25
$45.8M
Q3 25
$5.4M
$-35.1M
Q2 25
$-4.8M
$-14.8M
Q1 25
$4.8M
$137.1M
Q4 24
$19.4M
Q3 24
$-143.5M
$-44.6M
Q2 24
$18.9M
$-17.2M
Q1 24
$9.0M
$111.5M
Gross Margin
PCRX
PCRX
SPH
SPH
Q4 25
79.5%
64.7%
Q3 25
80.9%
64.7%
Q2 25
77.4%
61.7%
Q1 25
79.7%
58.8%
Q4 24
78.7%
60.6%
Q3 24
76.9%
59.4%
Q2 24
75.1%
62.9%
Q1 24
71.6%
61.8%
Operating Margin
PCRX
PCRX
SPH
SPH
Q4 25
1.2%
18.3%
Q3 25
3.5%
-7.9%
Q2 25
4.7%
2.1%
Q1 25
1.2%
27.0%
Q4 24
13.2%
15.8%
Q3 24
-82.8%
-10.8%
Q2 24
15.9%
3.2%
Q1 24
7.9%
27.5%
Net Margin
PCRX
PCRX
SPH
SPH
Q4 25
12.4%
Q3 25
3.0%
-16.6%
Q2 25
-2.7%
-5.7%
Q1 25
2.8%
23.3%
Q4 24
5.2%
Q3 24
-85.1%
-21.4%
Q2 24
10.6%
-6.8%
Q1 24
5.4%
22.4%
EPS (diluted)
PCRX
PCRX
SPH
SPH
Q4 25
$0.05
$0.69
Q3 25
$0.12
$-0.55
Q2 25
$-0.11
$-0.23
Q1 25
$0.10
$2.10
Q4 24
$0.38
$0.30
Q3 24
$-3.11
$-0.69
Q2 24
$0.39
$-0.27
Q1 24
$0.19
$1.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PCRX
PCRX
SPH
SPH
Cash + ST InvestmentsLiquidity on hand
$238.4M
$1.3M
Total DebtLower is stronger
$372.2M
$1.3B
Stockholders' EquityBook value
$693.1M
Total Assets
$1.3B
$2.4B
Debt / EquityLower = less leverage
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PCRX
PCRX
SPH
SPH
Q4 25
$238.4M
$1.3M
Q3 25
$246.3M
$405.0K
Q2 25
$445.9M
$1.3M
Q1 25
$493.6M
$3.9M
Q4 24
$484.6M
$4.4M
Q3 24
$453.8M
$3.2M
Q2 24
$404.2M
$4.9M
Q1 24
$325.9M
$4.4M
Total Debt
PCRX
PCRX
SPH
SPH
Q4 25
$372.2M
$1.3B
Q3 25
$376.7M
$1.2B
Q2 25
$580.5M
$1.2B
Q1 25
$583.4M
$1.3B
Q4 24
$585.3M
$1.3B
Q3 24
$1.2B
Q2 24
$1.2B
Q1 24
$1.2B
Stockholders' Equity
PCRX
PCRX
SPH
SPH
Q4 25
$693.1M
Q3 25
$727.2M
Q2 25
$757.8M
Q1 25
$798.5M
Q4 24
$778.3M
Q3 24
$749.6M
Q2 24
$879.3M
Q1 24
$892.2M
Total Assets
PCRX
PCRX
SPH
SPH
Q4 25
$1.3B
$2.4B
Q3 25
$1.3B
$2.3B
Q2 25
$1.5B
$2.3B
Q1 25
$1.6B
$2.4B
Q4 24
$1.6B
$2.4B
Q3 24
$1.5B
$2.3B
Q2 24
$1.6B
$2.3B
Q1 24
$1.6B
$2.3B
Debt / Equity
PCRX
PCRX
SPH
SPH
Q4 25
0.54×
Q3 25
0.52×
Q2 25
0.77×
Q1 25
0.73×
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PCRX
PCRX
SPH
SPH
Operating Cash FlowLast quarter
$43.7M
$-47.7M
Free Cash FlowOCF − Capex
$43.5M
$-67.5M
FCF MarginFCF / Revenue
22.1%
-18.2%
Capex IntensityCapex / Revenue
0.1%
5.3%
Cash ConversionOCF / Net Profit
-1.04×
TTM Free Cash FlowTrailing 4 quarters
$136.7M
$61.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PCRX
PCRX
SPH
SPH
Q4 25
$43.7M
$-47.7M
Q3 25
$60.8M
$41.8M
Q2 25
$12.0M
$95.5M
Q1 25
$35.5M
$40.1M
Q4 24
$33.1M
$8.8M
Q3 24
$53.9M
$36.8M
Q2 24
$53.2M
$61.4M
Q1 24
$49.1M
$75.1M
Free Cash Flow
PCRX
PCRX
SPH
SPH
Q4 25
$43.5M
$-67.5M
Q3 25
$57.0M
$27.7M
Q2 25
$9.3M
$80.9M
Q1 25
$26.9M
$20.8M
Q4 24
$31.0M
$-15.1M
Q3 24
$49.8M
$17.7M
Q2 24
$51.6M
$46.8M
Q1 24
$46.3M
$60.6M
FCF Margin
PCRX
PCRX
SPH
SPH
Q4 25
22.1%
-18.2%
Q3 25
31.7%
13.1%
Q2 25
5.1%
31.1%
Q1 25
15.9%
3.5%
Q4 24
16.6%
-4.0%
Q3 24
29.6%
8.5%
Q2 24
29.0%
18.4%
Q1 24
27.7%
12.2%
Capex Intensity
PCRX
PCRX
SPH
SPH
Q4 25
0.1%
5.3%
Q3 25
2.2%
6.7%
Q2 25
1.5%
5.6%
Q1 25
5.1%
3.3%
Q4 24
1.1%
6.4%
Q3 24
2.4%
9.1%
Q2 24
0.9%
5.8%
Q1 24
1.7%
2.9%
Cash Conversion
PCRX
PCRX
SPH
SPH
Q4 25
-1.04×
Q3 25
11.20×
Q2 25
Q1 25
7.37×
0.29×
Q4 24
0.45×
Q3 24
Q2 24
2.82×
Q1 24
5.47×
0.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PCRX
PCRX

EXPAREL$155.8M79%
ZILRETTA$33.0M17%
Iovera$7.0M4%

SPH
SPH

Propane$326.4M88%
Other Sales Revenue Net$19.9M5%
Fuel Oil And Refined Fuels$18.2M5%
Natural Gas And Electricity$5.9M2%
Wholesale$4.1M1%

Related Comparisons